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Abstract
Introduction: Necrosis at the tumor center is a common feature of aggressive breast cancers and has been associated 
with poor prognosis. It is commonly identified by means of invasive histopathology, which often correlates with 
morbidity and potential tumor cell dissemination, and limits the reconstruction of the whole necrotic domain. In this 
study we hypothesized that non covalent association to serum albumin (SA) and covalent binding to ligands for 
tumor-abundant cell receptors should synergistically drive selective accumulation and prolonged retention of imaging 
and therapeutic agents in breast tumor necrotic domains enabling in vivo identification, imaging and possibly 
treatment of such tumors.
Methods: Cyclo-Arg-Gly-Asp-D-Phe-Lys (c(RGDfK)) were conjugated to bacteriochlorophyll-derivatives (Bchl-Ds), 
previously developed as photodynamic agents, fluorescent probes and metal chelators in our lab. The c(RGDfK) 
component drives ligation to αVβ3 integrin receptors over-expressed by tumor cells and neo-vessels, and the Bchl-D 
component associates to SA in a non-covalent manner. STL-6014, a c(RGDfK)-Bchl-D representative, was i.v. injected to 
CD-1, nude female mice bearing necrotic and non-necrotic human MDA-MB-231-RFP breast cancer tumors. The 
fluorescence signals of the Bchl-Ds and RFP were monitored over days after treatment, by quantitative whole body 
imaging and excised tumor/tissue samples derived thereof. Complementary experiments included competitive 
inhibition of STL-6014 uptake by free c(RGDfK), comparative pharmacokinetics of nonconjugated c(RGDfK) Bchl-D (STL-
7012) and of two human serum albumin (HSA) conjugates: HSA-STL-7012 and HSA-STL-6014.
Results: STL-6014 and STL-7012 formed complexes with HSA (HSA/STL-6014, HSA/STL-7012). STL-6014, HSA-STL-7012 
and HSA-STL-6014, selectively accumulated at similar rates, in tumor viable regions over the first 8 h post 
administration. They then migrated into the necrotic tumor domain and presented tumor half lifetimes (T1/2) in the 
range of days where T1/2 for HSA-STL-6014 > STL-6014 > HSA-STL-7012. No accumulation of STL-7012 was observed. 
Pre-injection of c(RGDfK) excess, prevented the uptake of STL-6014 in the small, but not in the large tumors.
Conclusions: Non-covalent association to SA and covalent binding to c(RGDfK), synergistically enable the 
accumulation and prolonged retention of Bchl-Ds in the necrotic regions of tumors. These findings provide novel 
guidelines and strategy for imaging and treatment of necrotic tumors.
Introduction
Upon outgrowth of their oxygen supply, emerging tumors
develop hypoxic and eventually necrotic regions believed
to be the direct result of chronic ischemia caused by vas-
cular collapse when the rate of tumor cell growth exceeds
that of angiogenesis [1]. Initially, necrotic areas within
solid tumors constitute distinct morphologically identifi-
able regions that contain highly eosinophilic cells. Subse-
quently, this pattern is replaced by liquefaction necrosis,
in which the breakdown of cellular structures can be
observed [1]. Necrosis in invasive carcinoma of the breast
* Correspondence: avigdor.scherz@weizmann.ac.il
1 Department of Plant Sciences, Weizmann Institute of Science, Herzel Street, 
Rehovot, 76100, Israel
† Contributed equally
Full list of author information is available at the end of the articleGoldshaid et al. Breast Cancer Research 2010, 12:R29
http://breast-cancer-research.com/content/12/3/R29
Page 2 of 18
has been correlated with the concomitant angiogenesis,
development of high vascular density, and increased lev-
els of focal macrophage infiltration driven by chemotactic
factors [1-4].
Assessment of the degree of necrosis has been pro-
posed to serve as a powerful prognostic marker for differ-
ent cancer types [5-7]. Necrosis at the tumor center is a
common feature of aggressive breast cancer and has been
a s s o c i a t e d  w i t h  p o o r  p r o g n o s i s .  I n  p a r t i c u l a r ,  l a r g e
necrotic volumes in ductal carcinoma in situ (DCIS)
demonstrate tight correlation with comedo as opposed to
non-comedo DCIS [8]. Necrosis in this tumor type was
s h o w n  t o  b e  a s s o c i a t e d  w i t h  h y p o x i a  [ 4 ] ,  w h e r e  p r o -
longed hypoxic conditions were found to increase the
rates of mutations, tumor progression and angiogenesis,
and to promote metastatic potential and pre-growth sig-
naling pathways. In summary, the magnitude of necrosis
in mammary ducts appears to positively correlate and
possibly predict DCIS aggressiveness [9]. Necrotic and
hypoxic conditions constitute major impediments to suc-
cessful cancer therapy [10]. Therefore, increased detec-
tive resolution of hypoxic and necrotic tumors in vivo will
enhance diagnostic procedures and better outline the
tumor status for selection of appropriate treatment strat-
egies [11-14].
Necrosis and hypoxia are commonly identified by
means of invasive histopathology, which is often corre-
lated with morbidity and potential tumor cell dissemina-
tion. Thus, in situ diagnostic techniques, such as
magnetic resonance imaging (MRI) [15,16], blood oxy-
genation level dependent-MRI [17], diffusion-weighted
MRI [18] and positron emission tomography (PET) [19]
can be advantageous. However, insufficient vasculariza-
tion, linked with enhanced interstitial fluid pressure due
to the lack of lymphatic drainage, interfere with the con-
vectional uptake of small molecules used as therapeutic
or contrast agents in such detection protocols. At the
same time, enhanced tumor vascular permeability in
these regions drives extravasation of macromolecules
such as serum albumin (SA) from the circulation into the
tumor tissue, while the poor lymphatic drainage fosters
their retention within the tumor compartment [20,21].
Consequently, the 'enhanced permeability and retention
effect' (EPR), has been proposed as the basis for nonspe-
cific targeting of drugs comprising large molecules to
tumor tissue and has given rise to a new approach for
tumor-targeting drug design based on macromolecular,
micellar and lipidic particles (for a recent review see
Maeda and colleagues [22]). For example, non-covalent
association of styrene-maleic acid copolymer-conjugated
neocarzinostatin (16 kDa) with albumin, provides about
an 80 kDa complex that accumulates and exhibits reten-
tion in tumors of different origins [22]. Similarly, covalent
conjugation of the therapeutic agents mitomycin C-
bovine or indotricarbocyanine (ITTC) to SA, resulted in
their delivery to and accumulation/retention in tumors
and were even detected in the tumor necrotic domains
[23]. Gadophrin-2A, a porphyrin-based necrosis avid
contrast agents (NACA) used as an MRI contrast enhanc-
ing agent in necrotic tumor imaging, has been proposed
to accumulate in the margins of HT29 human colon
tumor necrotic zones, following delivery as a non-cova-
lent complex with SA either as is or after dissociation in
the tumor necrotic domain [24].
Recent studies showed better accumulation of NACA,
which have been conjugated to large molecules that func-
tion as ligands to over-expressed tumor cell receptors.
Thus, the ITTC accumulation in HT29 human colon
tumors was improved after its covalent conjugation to
transferrin in place of albumin, presumably because of
the transferrin interactions with the cancer cell surface
receptors [25]. However, such high molecular weight
complexes may elicit an immune response that should
prevent their frequent application as needed for imaging
and therapeutic applications. Thus, despite the advances
made in tumor-targeting techniques there is a clear need
to recruit new imaging principles and to expedite the
development of novel agents for such purposes.
In our quest for new imaging avenues, we postulated
that small contrast and/or therapeutic agents designed to
have the dual capacity of moderate association affinity to
SA and high affinity to tumor-specific receptors, would
allow for their prolonged accumulation in necrotic tumor
domains. We assumed that the EPR effect would assist
agent extravasation and retention in the tumor intersti-
t i u m  u p o n  f o r m i n g  a  c o m p l e x  w i t h  S A .  O n c e  i n  t h e
tumor tissue, the modified agents will dissociate from the
SA and preferentially bind to specific receptors, ensuring
active agent accumulation and possibly migration to the
necrotic domain by means of diffusion. Notably, the
design principle of such non-covalent complexes with SA
is profoundly different from the one underlying the make
up of covalent SA complexes [26].
In previous and ongoing studies, we have shown that
bacteriochlorophyll derivatives (Bchl-Ds) can be used as
therapeutic agents in photodynamic therapy by generat-
ing oxygen radicals upon in situ illumination [27-35].
WST11 and other Bchl-Ds were found to be highly effec-
tive in vascular-targeted photodynamic therapy in both
preclinical studies of different solid tumor types [27-32]
and in the clinical studies of prostate cancer [32-35]. In
addition, chemical modifications of the Bchl-D center, for
example by metal or proton substitution, render them
effective contrast agents for MRI [36], PET scan [37], and
fluorescence imaging protocols (described below).
Water-soluble Bchl-Ds, such as WST11 (Figure 1), circu-
late as non-covalent complexes with SA until clearance,
but despite this association they show no accumulation inGoldshaid et al. Breast Cancer Research 2010, 12:R29
http://breast-cancer-research.com/content/12/3/R29
Page 3 of 18
the tumor tissue and rapidly clear from the treated sub-
ject [28,38-40]. Thus, by covalent binding of Bchl-Ds to
tumor-specific ligands while retaining their SA complex-
ation ability, we are expecting to obtain contrast and ther-
apeutic agents that selectively accumulate in the tumor
necrotic domains, following the above working hypothe-
sis.
Herein, we examined the application of cyclic com-
pounds containing the Arg-Gly-Asp (RGD) sequence as
to impart tumor-specific ligands for targeting Bchl-Ds/
SA to necrotic tumor domains. The RGD motif is recog-
nized by many members of the integrin family [41]. More
specifically, c(RGDfK), and similar compounds demon-
strated significant affinity to αVβ3 integrin receptors that
are abundant in several cancer cell lines and in the rapidly
developing neo-vasculaturization near necrotic tumor
domains. Hence, RGD-containing molecules have been
suggested to provide new opportunities for selective
tumor targeting of imaging and therapeutic agents [42].
One of the problems with such application is the short
life-time of the small RGD complexes in the circulation
(two to three minutes lifetimes for c(RGDfK) [43]. The
covalent binding of cyclic RGD to macromolecules such
as human SA (HSA), results in a better accumulation of
the cyclic RGD compound in tumors probably because of
the significantly enhanced life time of the RGD-HSA
complex in the circulation compared with the free RGD
[26] and the involvement of the aforementioned EPR
effect. However, as noted above the resulted protein com-
plex may be immunogenic and therefore of limited use in
the clinical arena. Hence, mobilization of the therapeutic
or contrast agents by reversible, non-covalent association
in situ with circulating SA, as proposed in the present
study, is expected to be advantageous.
Recently, we synthesized and tested the uptake by
tumors of STL-6009, a c(RGDfK)-conjugated WST11
(Figure 1, [37,44]). The compound selectively accumu-
lated to significant concentrations (4 to 8 μM) in primary
xenografts in mice. These concentrations mirrored the
circulating Cmax  values recorded for nonconjugated
WST11 using inductively coupled plasma mass spectros-
copy measurements. STL-6009 accumulation exhibited
tight dependence on the presence of αVβ3 receptors in
the respective tumor cell lines and on the extent of neo-
vascularization in the xenograft model [37]. However, the
weak fluorescence of STL-6009 due to the central palla-
dium (Pd) atom [45], impaired the clarity of on-line fluo-
rescence imaging, rendering its further development for
imaging purposes futile. Thus, in the present study the
central Pd atom was substituted by two protons yielding
STL-6014 (Figure 1), a novel RGD-Bchl-D conjugate that
emits 100-fold stronger fluorescence than its Pd-chelated
counterpart. STL-6014 uptake was monitored in mice
bearing MDA-MB-231-red fluorescence protein (RFP)
breast tumors with and without central necrosis and
compared with that of the following compounds: (1) STL-
7012, an RGD-free analog; (2) HSA-STL-6014; and (3)
HSA-STL-7012. The experimental findings combined
with some literature data strongly support the above sug-
gested hypothesis. Namely, non-covalent association to
SA, and covalent binding to ligands of tumor-abundant
cell receptors, synergistically drive selective accumulation
and prolonged retention of agents in the necrotic
domains of breast tumors, enabling the in vivo imaging of
such necrotic tumors.
Figure 1 Structures of Bchl-Ds. Values in parenthesis are the HSA association constants Ka(HSA), of each bacteriochlorophyll derivative (Bchl-D; 1/μM).Goldshaid et al. Breast Cancer Research 2010, 12:R29
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Materials and methods
Materials
Bchl-D preparation
Bchl-Ds including 31-oxo-15-methoxycarbonylmethyl-
Rhodobacteriochlorin 131-(2-sulfoethyl)amide dipotas-
sium salt (STL-7012, Figure 1a), and its palladium com-
plex (WST11, Figure 1b), 31-oxo-15-
methoxycarbonylmethyl-Rhodobacteriochlorin 131-(2-
sulfoethyl)amide-173-c(RGDfK)amide potassium salt
(STL-6014, Figure 1c), and its palladium complex (STL-
6009, Figure 1c), were prepared as previously described
[37,38]. The Bchl-Ds were dissolved in 5% aqueous man-
nitol and adjusted to a pH of 7.2 to 7.4 with Tris HCl (10
mM tris(hydroxymethyl) aminomethane in 5% aqueous
mannitol). The obtained solutions were filtered through
0.2 μm polytetrafluoroethylene (PTFE) filters (National
Scientific, Rockwood Tennessee, USA). Concentrations
were spectrophotometrically determined in methanol at
747 nm, using molar extinction coefficients of 1.2 × 105
M-1cm-1 for Pd-containing and 6.3 × 104 M-1cm-1 for Pd-
free compounds. The solutions were stored in the dark at
-20°C until use.
HSA-STL-6014 and HSA-STL-7012 preparation
c(RGDfK)-bacteriopheophorbide a (Bpheid) was synthe-
sized via activation of Bpheid [38] with N-hydroxysuccin-
imide (NHS) and N,N-dicyclohexylcarbodiimide (DCC)
in tetrahydrofuran, followed by purification of activated
esters on silica column and then reaction with two-fold
molar excess of c(RGDfK) in dimethylformamide (DMF)
in the presence of triethylamine under argon atmosphere
overnight (yield about 85%). Aminolysis of Bpheid-
c(RGDfK) and Bpheid dissolved in chloroform-methanol
mixture was induced with bis(3-aminopropyl)amine
(yield >90%). The resulting Bchl-Ds were first purified
using n-butanol-water extraction, and then by High-per-
formance liquid chromatography (HPLC), using C18-col-
umn and acetonitrile-water gradient. HSA (90 mg) was
activated with sulfoNHS and 1-Ethyl-3-(3-dimethylamin-
opropyl)carbodiimide hydrochloride (EDAC) (sul-
foNHS:EDAC:HSA = 1000:500:1 molar ratio) in 50 mM
phosphate buffer, pH 5.0. After 45 minutes, a sample of
the reaction mixture (about 1 mL) was passed through
PD-10 column (Sephadex G-25 M, GE Healthcare, Upp-
sala, Sweden) using 5 mL of the same buffer to recover
the protein fraction (HSA-sNHS). Bchl-Ds (about 20 mg
each) were dissolved in DMF (2 mL) and added to 2 mL
HSA-sNHS, diluted with 4 mL of 50 mM phosphate buf-
fer, pH 8.0, and 1 ml of 5% mannitol. Reaction mixtures
were sonicated and stirred overnight under argon atmo-
sphere, then evaporated to remove DMF, re-dissolved in
water and passed again through PD-10 column for collec-
tion of Bchl-D-HSA-conjugates. To remove non-cova-
lently bound Bchl-D, the products were evaporated and
extracted several times with methanol. The extent of
HSA conjugation was calculated from the molar ratios
between the Bchl-D and HSA parts, determined spectro-
photometrically and by Bradford assay, respectively.
Approximately 10% of HSA was conjugated. Aliquots of
conjugates equal to 0.7 nmol Bchl-D, were prepared for
injections.
Cell culture
MDA-MB-231 breast cancer cells were obtained from the
American Type Culture Collection (Manassas, VA, USA).
MDA-MB-231-RFP were generated by stable transfection
of the cell line with pDsRed-Monomer-Hyg-C1 (Clon-
tech, Palo Alto, CA, USA), which carries the hygromycin
resistance gene in which the DsRed-Monomer gene was
replaced with pDsRed2 (from pDsRed2-N1 plasmid,
Clontech, Palo Alto, CA, USA). Lipofectamine™ 2000
(Invitrogen, Carlsbad, California, USA) was used for the
transfection process according to the manufacturer's pro-
tocol. Stably RFP-expressing cells were then cloned and
maintained in RPMI 1640 medium supplemented with 1
mmol/L sodium pyruvate, 10% fetal calf serum, 250 μg/
ml hygromycin, 0.06 mg/ml penicillin and 0.1 mg/ml
streptomycin.
Association constants of Bchl-Ds to HSA
Association constants of Bchl-Ds to HSA were deduced
from spectroscopic measurements of the ratio between
Bchl-Ds and HSA for different concentrations of HSA
using both factor analysis, as previously described [38]
and by monitoring changes in the near infrared (NIR)
absorption of the Bchl-Ds during titration with HSA.
Briefly, all four Bchl-Ds present broad NIR absorption
with reduced intensity in SA-free aqueous solutions.
Upon addition of SA, they form 1:1 complexes with the
added protein ((Bchl-D)/SA) with strong and narrow NIR
absorption bands. The narrow-band absorption is pro-
portional to the ((Bchl-D)/SA) concentration enabling
calculation of the association constant Ka through the
following equation:
Where [SA]0  is the analytical concentration of the
added SA and [(Bchl-D/SA)] is the concentration of the
Bchl-D complex with SA calculated from the spectral
changes.
Animals
Female, CD-1, nude mice (7 to 8 week old, about 25 g)
were housed and handled with ad libitum access to food
and water at the Core Animal Facility according to Insti-
tutional Animal Care and Use Guidelines. All experimen-
tal procedures were approved by the Institutional Animal
Ka
Bchl D SA
SA Bchl D SA Bchl D
=
−
−− × −
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Care and Use Committee at the Weizmann Institute of
Science (Rehovot, Israel).
Mouse tumor model
Mammary fat pads (left, bottom nipple) of female mice
were inoculated with harvested MDA-MB-231-RFP
human breast cancer cells (4 × 106 in 100 μl saline).
Tumors were classified as 'small' (≤100 mm3) at one to
two weeks from time of cell injection, or 'large' after three
to four weeks (necrotic tumors, 250 to 500 mm3). To
avoid tumor burden, mice were sacrificed (cervical dislo-
cation) when tumor size reached 10% of body weight or at
90 days post-implantation. External caliper measure-
ments, length (L), width (W) and depth (D) were used to
calculate in vivo tumor volume according to the formula:
V = L/2 · W/2 · D/2 · π · 4/3 [46].
Whole-body fluorescence imaging
The in Vivo Optical Imaging System (IVIS®100/XFO-12,
Xenogen Corp., Alameda, CA, USA) was used to acquire
fluorescent images of the RFP-expressing tumors, as well
as Bchl-D compounds associated with tissues and organs
after their intravenous (i.v.) infusion to the tested ani-
mals. The field of view was 15 cm. RFP fluorescence, in
units of photons/sec, was detected using 525/50 nm and
612/75 nm filter sets for excitation and emission, respec-
tively, with one second integration time. NIR fluores-
cence of the different Bchl-Ds, in units of photons/sec,
was detected using 680/30 nm and 847/75 nm filter sets
for excitation and emission, respectively, at an integration
time of five seconds. Background fluorescence for all
quantitative analyses was calculated by recording the
average fluorescence (photons/sec)/cm2 from three ani-
mals in three different areas around and within the tumor
of untreated animals provided with a similar diet for
three days before measurements.
Drug accumulation was determined following i.v.
administration of molar equivalents of the Bchl-D moiety
to the tail vein of mice fed with a chlorophyll-free, puri-
fied diet (Harlan Teklad, Harlan Laboratories, Indianapo-
l i s ,  I N ,  U S A )  f o r  t h r e e  d a y s  b e f o r e  a d m i n i s t r a t i o n  ( i n
order to reduce skin and food autofluorescence). Before
imaging, mice were anesthetized by intraperitoneum
injection of a 30 μl mixture of 85:15 ketamine:xylazine.
Xenogen Living Image Software (Xenogen Corp.,
Alameda, CA, USA) was used for sequential fluorescent
image acquisition [see Additional file 1] and superimposi-
tion of photographic images of mice and color-coded flu-
orescent images. Statistical analysis was performed using
Origin8.1 (OriginLab, Northampton, Massachusetts,
USA) and SPSS15 (SPSS Inc, Chicago, Illinois, USA) soft-
wares.
Biodistribution studies
Anaesthetized mice were i.v. injected with 15 mg/kg STL-
6014 (n = 27) or 9 mg/kg STL-7012 (n = 15). At each indi-
cated time point, three animals were sacrificed and blood,
kidney, liver and tumor tissues were collected into pre-
weighed vials and frozen at -20°C. Tissue samples were
homogenized in methanol (100 mg tissue/ml) and
extracted the next morning by centrifugation (13,000 × g
five minutes) at room temperature. Supernatants were
diluted in methanol by a factor of two and drug concen-
tration was determined by fluorescence measurements
(Varian - Cary Eclipse spectrofluorimeter, Palo Alto, Cal-
ifornia, USA) at 750 nm (peak values). Drug concentra-
tions were interpolated from a fluorescence calibration
curve, based on predetermined drug concentrations
using absorption spectroscopy.
In vivo competition between STL-6014 and free c(RGDfK) in 
MDA-MB-231-RFP tumors
STL-6014 (140 nmol, 7.5 mg/kg) was i.v. injected to the
tail vein of mice one hour after being pre-injected with an
excess (8.5 μmol) of c(RGDfK) free peptide. Whole-body
fluorescence images were recorded up to 24 hours post-
STL-6014 injection (IVIS®, Xenogen Corp., Alameda, CA,
USA) with the respective filter settings, described above.
Histology and in vitro calculations of tumor and necrosis 
volumes
Tumors were surgically removed from sacrificed mice,
fixed in 3.7% formaldehyde, and embedded in paraffin
blocks. Tumors were serially dissected to 4 μm slices with
a separation of 0.5 mm between consecutive slices. Slices
were stained with H&E under standard conditions and
evaluated for pathological markers (E800 microscope
equipped with a Nikon DXM1200 digital camera, magni-
fication × 0.6, objective × 0.5, Nikon, Tokyo, Japan).
Tumor volume (Tv), necrosis volume (Nv), the total
tumor area (Ta) and necrotic area (Na) of each slice were
calculated using Image Pro Plus 0.5 software. Tv and Nv
were calculated using the following equations:
where n is the number of slices for the evaluated tumor.
Tvm m T a T a ii
i
n
() . ( ) 3
1
1
05 =+ +
= ∑
Nv mm Na Na ii
i
n
() . ( ) 3
1
1
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= ∑Goldshaid et al. Breast Cancer Research 2010, 12:R29
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Results
Necrotic MDA-MB-231-RFP tumor model
Small (≤100 mm3) and large (250 to 500 mm3) MDA-MB-
231-RFP tumors were excised at pre-defined time inter-
vals after cell inoculation for morphological analysis.
Large tumors (Figures 2a to 2d) featured an extensive
central eosinophilic and often hypereosinophilic (Figures
2b and 2c) necrotic domain with widespread karyolysis
and minimal karyorrhexis and pyknosis (Figure 2d). In
addition, mild, multifocal, neutrophilic infiltration was
seen at the margins of the necrotic tissue. Viable areas
were limited to the periphery of the tumor and included
disorganized proliferation of neoplastic cells arranged
into dense cellular sheets. The neoplastic cells were
round to irregular with a high nuclear/cytoplasmic ratio
and irregular vesicular nuclei (Figure 2d). Figures 2e to 2h
are representatives of small tumors, and illustrate homog-
enous tissue with no evidence of necrosis.
Above 90% of the large tumors (n = 30, 250 mm3 ≤Tv
≤500 mm3), presented central necrosis that occupies
about 50% of Tv. Five to ten percent of the large tumors (n
= 2) presented smaller volume of necrosis (about 50 mm3,
about 15% of Tv). Conversely, more than 90% of the small
tumors (n = 20, Tv ≤ 100 mm3) presented almost no
necrosis. In 10% or less of these tumors (n = 2) a central
necrosis (Tv ≤ 15 mm3 ≤20% of Tv) is observed. Thus,
central necrosis appears to correlate only with large
tumors of MDA-MB-231-RFP cells in this mouse model.
STL-6014 uptake into orthotopic MDA-MB-231-RFP tumors
The tumor-targeting capabilities of RGD-conjugated
Bchl-Ds, was tested by following the accumulation of i.v.
injected STL-6014 in mice bearing large or small MDA-
MB-231-RFP tumors.
Large tumors
Dynamic, whole-body fluorescence imaging was first per-
formed at specific times for up to seven days after drug
injection to mice with large tumors (n = 9, Figures 3a and
3b, upper panels). Nine days follow-up is further pro-
vided in additional file 2. The location and sizes of the
respective tumors were verified by whole-body RFP fluo-
rescence scans (Figures 3a and 3b, lower panels). Exten-
sive fluorescence was detected throughout the animal
body within the first 15 minutes after STL-6014 injection
(Figure 3a, upper panel), reflecting high levels of circulat-
Figure 2 Macroscopic and microscopic features of large and small MDA-MB-231-RFP tumors. Small (about 100 mm3) and large (250 to 500 
mm3) orthotopically-grafted MDA-MB-231-RFP tumors were excised at pre-defined time intervals from cell inoculation. (a) Macroscopic appearance 
of a cross section of a freshly excised large tumor. The bulk of the mass is composed of opaque, necrotic tissue, while the viable tissue is limited to the 
rim. (b) Subgross appearance of the tumor shown in (a). There is very good correlation between the macroscopic and microscopic features. The ne-
crotic tissue in the center is partly surrounded by a rim of viable tissue. (c) Medium magnification of the boxed area in (b). The interface between ne-
crotic (N) and viable (V) tissue is indicated with asterisks. (d) High magnification of a region at the interface between necrotic (N) and viable (V) tissues. 
The border between the two zones is marked by a black line. Areas with predominant karyolysis (1, pink tissue) and predominant karyorrhexis (2, gran-
ular basophilic nuclear debris) are identified. (e) Macroscopic appearance of a cross section of a freshly excised small tumor. The tissue is homogenous 
and there is no evidence of necrosis. (f) Subgross appearance of the small tumor shown in (e) at the same magnification as (b). (g) At slightly higher 
magnification, the homogenous appearance of the tumor is evident. (h) Boxed area - neoplastic viable cells; Arrowheads - mitotic structures.Goldshaid et al. Breast Cancer Research 2010, 12:R29
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Figure 3 Accumulation of STL-6014 in large and small MDA-MB-231-RFP tumors. CD-1 nude, female, mice bearing orthotopically-grafted MDA-
MB-231-RFP tumors were intravenously injected with STL-6014 (15 mg/kg). Fluorescent images of (a and b) large (n = 9) and (c and d) small (n = 10) 
tumors, were taken at the indicated times post-injection. Upper panels - near infrared (NIR) fluorescence images indicate STL-6014 distribution, lower 
panels - red fluorescence images indicate tumor size and location. (a) Fluorescence signals in a large tumor over the first nine hours post-administra-
tion. (b) Fluorescence signals in the large tumor over the following one to seven days post-administration. (c) Fluorescence signals in a small tumor 
over the first 9.5 hours post-administration. (d) Fluorescence signals in the small tumor over additional one to three days post-administration. Longi-
tudinal STL-6014 decay curves in representative (e) large and (f) small tumors. Total fluorescence intensity within the individual tumor boundaries, 
was normalized per unit area and expressed as photon/(sec × cm2). Other details are as indicated in the methods section.Goldshaid et al. Breast Cancer Research 2010, 12:R29
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ing drug in the blood and clearance organs (i.e. liver, kid-
ney). On day one post-administration, STL-6014 had
markedly accumulated in the tumor, relative to the sur-
rounding tissue, with considerably lower levels in the
abdominal clearance organs. On day three, the clearance
organs appeared to be almost STL-6014-free, while the
fluorescence in the tumor was retained (Figure 3b, upper
panel). The fluorescence intensity in the individual clear-
ing organs at the relevant time points [see Additional file
3], correlate well with the regional fluorescence decline in
the whole body images.
Small tumors
Accumulation of STL-6014 in small tumors (n = 10) was
assessed under the same experimental conditions but
appeared markedly different (Figures 3c and 3d).
Although peak fluorescence of the injected drug was evi-
dent within the tumor at six to eight hours after injection
(Figure 3c, upper panel), its level relative to the surround-
ing tissue was rather small. Tumor fluorescence returned
to background values within 48 h of drug injection (Fig-
ures 3c and 3d).
Quantitative assessment of the STL-6014 dynamic 
fluorescence in small and large tumors post i.v. 
administration
The temporal evolution and decay of STL-6014 fluores-
cence density ((number of photons at (810 to 870 nm))/
(sec × cm2 tumor tissue)) was calculated and presented
versus time for mice bearing large tumors (n = 9, Figure
3E) or small tumors (n = 10, Figure 3f). In both tumor
types, STL-6014 concentrations peaked within six to
eight hours of administration. This period of accumula-
tion was then followed by a mono-exponential decay in
the small tumors, with an average t1/2 value of 14.0 ± 1.5
(SD) hours (R2 ≥ 0.97, P < 0.001, n = 10). In contrast,
clearance from the large, necrotic tumors exhibited a bi-
exponential decay with average t1
1/2 values of 12.0 ± 3.5
hours during the first 24 hours and t2
1/2 of 210.0 ± 86.0
hours thereafter (R2 ≥ 0.98, P < 0.001, n = 9). No statisti-
cally significant difference was seen between the fluores-
cence decay constant in small tumors and the first decay
constant of large tumors. Large tumors maintained sig-
nificant concentrations of STL-6014 for prolonged peri-
ods, as evident by the tumor fluorescence still detectable
at nine days, and similar to the levels detected on day
seven post-administration [see Additional file 2]. Thus,
the emerging situation is of a relatively rapid-in slow-out
pattern of accumulation. These results were substanti-
ated by detailed analysis of drug concentrations in the dif-
ferent organs/tissues, as described in the 'biodistribution
and pharmacokinetics analysis' section below.
Notably, the RFP fluorescence from the tumor cells
declined shortly after STL-6014 infusion (Figures 3a to 3d
lower panels) and then increased again at rates that
appeared to mirror the uptake (first hours) and clearance
of the STL-6014 from the corresponding tumors. Hence,
this phenomenon provides independent evidence for the
differential accumulation and clearance patterns of STL-
6014 in small and large tumors [see Additional file 4].
Selective STL-6014 accumulation in the necrotic domain of 
MDA-MB-231-RFP tumors
Figure 3 shows that the fluorescence of STL-6014 accu-
mulates and then clears very slowly from large MDA-
MB-231-RFP tumors whereas clearance from small
tumors is more than 10-fold faster (see above). As more
than 90% of the large tumors have large necrotic volumes
and more than 90% of the small ones are non-necrotic,
we propose that t1
1/2 and t2
1/2 monitor clearance of STL-
6014 from the viable and necrotic tumor domains,
respectively. An alternative possibility is that the slow flu-
orescence decay in the large tumors reflects diffusion
barriers that are related with the tumor volume regardless
of the necrosis. Hence, we next examined the relation
between prolonged accumulation of STL-6014 within the
tumors (on days five and seven post administration for
small and large tumors, respectively) and tumor necrosis
that was independently assessed by tumor dissection and
histopathology as described above, following the whole
body dynamic assay. We thus obtained four tumor
classes: (1) typical large tumors (Tv ≥ 250 mm3, Nv ≥ 150
mm3); (2) non-typical large tumors (Tv ≥ 250 mm3, Nv
about 50 mm3); (3) typical small tumors (Tv ≤ 100 mm3,
Nv ≤ 6 mm3), and (4) non-typical small tumors (Tv ≤ 100
mm3, Nv about 10 to 20 mm3). The left panel in Figure 4
illustrates representative histological sections and STL-
6014 fluorescence images from the whole body and dis-
sected tumors of groups number 1 and number 2, and the
right panel of groups number 3 and number 4. These
images clearly show that the STL-6014 fluorescence only
sustains prolonged high intensity in tumors with large Nv
values. This conclusion is substantiated by the observa-
tions that animal number 1 in Figure 4 left panel (Nv =
151 mm3) presents significantly higher fluorescence than
animal number 2 (Nv = 54 mm3) although their Tv values
are similar. Thus, as more than 90% of the large tumors
are necrotic and more than 90% of the small tumors are
non-necrotic, this experiment shows that prolonged fluo-
rescence of STL-6014 at more than three days post injec-
tion is associated with large Nv and not Tv.
Next, the spatial distribution of the STL-6014 was
monitored in dissected typical large tumors by following
its fluorescence at eight time points (10 minutes, 1, 4, 16,
and 24 hours and 3, 5, and 7 days, n = 3 for each time
point). Images for representative time points are shown
in Figure 5 and additional file 5. At four hours post injec-
tion, STL-6014 signal was observed within the viableGoldshaid et al. Breast Cancer Research 2010, 12:R29
http://breast-cancer-research.com/content/12/3/R29
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Figure 4 Correlation between necrotic volumes and STL-6014 accumulation in MDA-MB-231-RFP tumors. CD-1 nude, female mice bearing 
MDA-MB-231-RFP tumors orthotopically grafted to the mammary fat pad were intravenously injected with STL-6014 (15 mg/kg). Images of large (an-
imals #1,2) and small (animals #3,4) tumors were taken at seven and five days, respectively, post-injection. (a) Red fluorescence protein (RFP) fluores-
cence images indicate tumor size and location. (b and c) Near infrared (NIR) fluorescence images demonstrating STL-6014 distribution both in vivo 
and after dissection, respectively. (d) Color photos. (e) Tissue sections of the tumor center stained with hematoxylin and eosin.Goldshaid et al. Breast Cancer Research 2010, 12:R29
http://breast-cancer-research.com/content/12/3/R29
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Figure 5 STL-6014 accumulation in the necrotic area of large orthotopic MDA-MB-231-RFP tumors. CD-1 nude, female mice (n = 3) bearing an 
orthotopically grafted, large MDA-MB-231-RFP tumor were intravenously injected with 15 mg/kg STL-6014. Whole-body and excised tumor images 
were taken at 4 hours, 16 hours, and 3 days post-injection. Upper panels - in vivo images, lower panels - images of excised tumors. (a and d) Color 
photos. (b and e) Red fluorescence images for detection of tumor location and size. (c anf f) near infrared (NIR) fluorescence images for detection of 
STL-6014 distribution. All other details are as described in the methods section. ND, necrotic domain, VD, viable domain.Goldshaid et al. Breast Cancer Research 2010, 12:R29
http://breast-cancer-research.com/content/12/3/R29
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tumor region alone. At 16 hours post-injection, a distinct
signal intensification was observed towards the center of
the necrotic domain. Beyond that time point, fluores-
cence was only observed in the necrotic domain. Impor-
tantly, the clear demarcation between the RFP
fluorescence (originating in the tumor viable domain)
and the STL-6014 fluorescence (from the necrotic
domain) did not shift towards the tumor center during
these days of examination (Figure 5) [see also Additional
file 5].
Cumulatively, these results illustrate progressive accu-
mulation and selective retention of STL-6014 within the
necrotic tumor domain after temporary lodging in the
tumor viable region.
Biodistribution and pharmacokinetics of STL-6014
STL-6014 levels in blood, liver, kidney and large MDA-
MB-231-RFP tumors were assessed at the indicated time
points (Figure 6a). STL-6014 reached peak concentra-
tions in the tumors at eight hours post-injection (11 μg
drug/gr tumor tissue; about 3.0% of the initial drug dose),
while its levels in the normal tissues examined peaked at
less than five minutes post-injection and cleared to nearly
background levels within less than 72 hours Tumor STL-
6014 levels were about two orders of magnitude higher
than in the blood during the 48 to 72 hours post-adminis-
tration period (Figure 6a, insert), about 10-fold higher
than in the spleen, heart, brain, fat and muscle (data not
shown), and approximately two-fold higher than in the
kidney, liver (Figure 6a, insert), intestines, lung and skin
(data not shown). STL-6014 underwent rapid hepatic
clearance with a t1/2 of about four hours. Because of the
relatively fast clearance of STL-6014 from the non-
necrotic tumors, the fluorescence difference between the
tumor and the surrounding normal tissue sustained for
short time accounting for the poor imaging of these
tumors as presented in Figures 3c and 3d. These results
substantiate our hypothesis that STL-6014 and similar
agents can be used for selective imaging of necrotic
tumors.
Is the c(RGDfK) moiety essential for the STL-6014 uptake by 
the tumor?
In order to examine if the RGD moiety is imperative for
the selective uptake of STL-6014 by the tumor, we com-
pared its time-dependent accumulation within tumors,
with that of the RGD-free STL-7012 (Figure 1). Quantita-
tive assessment of the STL-7012 fluorescence intensity
from tissues extracts was performed (Figure 6b) showing
no STL-7012 accumulation in the tumor at any time lon-
ger than one hour post administration. No specific tumor
fluorescence of STL-7012 was seen in mice bearing large,
necrotic tumors, already at one hour post i.v. injection
(Figure 7, n = 3). Similar results were obtained in mice
bearing small tumors (data not shown). These findings
clearly indicate that the c(RGDfK) moiety is imperative to
Bchl-D accumulation and retention in both small and
large tumors.
The role played by the Bchl-Ds association to SA in their 
uptake and prolonged accumulation in the MDA-MB-231-
RFP tumors
In our previous studies [28,38] we have demonstrated
that the water soluble WST11 is primarily carried in the
circulation through non-covalent associations with SA.
However, such non-covalent association appears insuffi-
cient to drive tumor accumulation and retention of
WST11 [44] and STL-7012 (Figures 6b and 7). On the
other hand when STL-7012 was covalently bound to
HSA, it presented some accumulation and prolonged
retention in the tumor (Figures 8b and 8c) and HSA-STL-
6014, appears to clear extremely slowly, if at all, from the
tumor (Figures 8a and 8c). These findings corroborate
with the aforementioned finding that covalent binding or
non-covalent association of contrast agents with SA, sig-
nificantly enhances their uptake by tumors [26].
Does the Bchl-D conjugation to the c(RGDfK) increases its 
binding affinity to SA and thereby tumor accumulation and 
retention?
Following the above findings, it may be suggested that
stronger binding of STL-6014 to SA compared with
RGD-free STL-7012 analogue, accounts for the increased
accumulation of the former in tumors. Therefore, we set
out to determine the association constants of the four
Bchl-Ds presented in Figure 1 to HSA. The derived con-
stants (Figure 1, in parenthesis) were found to be within
the same order of magnitude. In fact, those for the RGD
conjugates were four to six fold lower than the associa-
tion constants of their RGD-free analogues, ruling out
stronger SA association as the sole basis for STL-6014
retention in the tumor.
In summary, association to SA appears to be important
for the uptake of Bchl-Ds to the necrotic tumor domain,
but is not enhanced by the RGD moiety.
Does the contribution of the RGD moiety involve 
association with tumor-specific cell receptors?
As c(RGDfK) was found not to enhance the non-covalent
association of the Bchl-Ds moiety (e.g. STL-7012) with
circulating SA, emphasis was placed on defining the role
of RGD in STL-6014 uptake by the tumor. The possible
involvement of a specific RGD binding site such as αVβ3
integrin in the observed drug accumulation within
tumors was next examined by designing a competition
assay between STL-6014 and free c(RGDfK).
Small tumors
STL-6014 (7.5 mg/kg, 140 nmols/mouse) was i.v. injected
to mice bearing small tumors one hour after the injectionGoldshaid et al. Breast Cancer Research 2010, 12:R29
http://breast-cancer-research.com/content/12/3/R29
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Figure 6 Biodistribution of STL-6014 and STL-7012 in MDA-MB-231-RFP tumor-bearing mice. CD-1 nude, female mice (n = 3 for each time 
point) were intravenously injected with: (a) 15 mg/kg STL-6014 or, (b) 9 mg/kg STL-7012 and sacrificed at the indicated times. Tissue samples were 
collected for STL-6014 or STL-7012 extraction. Values represent averaged fluorescence intensities (± standard deviation), measured as described in the 
methods section.Goldshaid et al. Breast Cancer Research 2010, 12:R29
http://breast-cancer-research.com/content/12/3/R29
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of a 61-fold molar excess of free c(RGDfK) (Figure 9).
When delivered alone, STL-6014 fluorescence was
retained within the tumor throughout the experiment
(Figure 9a). In contrast, in the presence of free c(RGDfK),
competing for the same binding sites (Figure 9b), almost
no STL-6014 fluorescence was detected in the tumor.
Thus, the RGD moiety plays a critical role in drug uptake
to small tumors by interacting with specific receptors in
the tumor tissue.
Large tumors
A similar competition experiment was performed for ani-
mals with large tumors. However, in this case the uptake
and accumulation of STL-6014 was not affected by the
pre-administration of free c(RGDfK) (data not shown).
Discussion
Preferential targeting of contrast and therapeutic agents
for detection, imaging and treatment of tumors is under-
stood to bear great prospects for effective cancer man-
agement. Of particular significance is the early, in situ
detection of necrotic tumors in patients with localized
breast cancer. This is critical for the appropriate selection
of a treatment approach.
This study introduces a new strategy for in vivo imaging
of necrotic breast tumors, following the design of Bchl-D-
based agents that associate non-covalently with circulat-
ing SA immediately upon i.v. administration, and contain
ligands with acute affinity for tumor-specific receptors.
The moderate association of Bchl-D with SA was postu-
lated to assist extravasation and temporal retention of the
Bchl-RGD molecules by the necrotic tumor domains, via
the EPR effect, while their strong affinity to tumor-spe-
cific receptors would maintain prolonged residence in
these domains.
To test this hypothesis, we introduced the STL-6014
conjugate (Fig. 1) to mammary tumor-bearing mice.
Although STL-6014 moderately associates with SA (Ka =
1.2 × 105M-1, Figure 1), the c(RGDfK) moiety has been
shown to strongly associate (Ka about 109M-1) with αVβ3
integrin receptors abundant in the tumor vasculature, the
cell membrane of some cancer cells [42] and on mac-
rophages that infiltrate to the tumor tissue. Hence,
c(RGDfK) was expected to provide high tumor affinity to
the tested RGD-Bchl-D conjugates during their circula-
tion as complexes with SA.
By correlating the red fluorescence of the RFP-express-
ing cancer cells and the NIR fluorescence emitted by the
different Bchl-Ds, we monitored the dynamics of their
biodistribution, as well as their accumulation in the
tumor, prolonged retention and compartmentalization in
the tumor sub-domains. The presented data demonstrate
that conjugation to c(RGDfK) and complexation with SA
synergistically enhances the tumor uptake and retention
of the tested RGD-Bchl molecules in tumor necrotic
domains. The c(RGDfK) moiety was shown to be essen-
tial for tumor-specific drug accumulation, as evidenced
by the lack of free unconjugated Bchl-D uptake (Figure 7)
[44]. On the other hand the half life of STL-6014 (Figure
Figure 7 The role of the c(RGDfK) moiety in driving Bchl-D accumulation within tumors. CD-1 nude, female mice (n = 3) bearing an orthotopi-
cally grafted, large MDA-MB-231-RFP tumors were intravenously injected with 9 mg/kg STL-7012. Drug accumulation was monitored, by means of 
fluorescence imaging, for up to three days and a representative animal is shown. Upper panel - near infrared (NIR) fluorescence images indicate bac-
teriochlorophyll derivative (Bchl-D) distribution and lower panel - Red fluorescence images indicate tumor location.Goldshaid et al. Breast Cancer Research 2010, 12:R29
http://breast-cancer-research.com/content/12/3/R29
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3 )  w a s  m u c h  l o n g e r  e v e n  i n  s m a l l  t u m o r s  ( a b o u t  1 2
hours) than that of free c(RGDfK) molecules in a similar
animal model (minutes) [43]. This role is further demon-
strated by the significantly slower clearance of the HSA-
STL-6014 covalent conjugate compared with the HSA/
STL-6014 complex (Figure 8c) and the HSA-7012 cova-
lent conjugates (Figures 8b and 8c) compared with HSA/
7012 complexes (Figures 6b and 7). The same observa-
tions were recently made after i.v. administration of STL-
6009, a non-fluorescent c(RGDfK)-(Pd)Bchl-D [44].
As the c(RGDfK) moiety was found not to increase the
Bchl-Ds association to the SA, its key role presumably
reflects the hypothesized affinity to particular receptors
in the tumor tissue. Intense affinity to αVβ3 integrins
Figure 8 Accumulation of HSA-STL-6014 and HSA-STL-7012 in large MDA-MB-231-RFP tumors. CD-1 nude, female, mice bearing orthotopically 
grafted, large MDA-MB-231-RFP tumors were intravenously injected with 0.7 nmol (a) HSA-STL-6014 or (b) HSA-STL-7012. Fluorescence images of the 
tumors were taken at the indicated times post-injection. Upper panel - near infrared (NIR) fluorescence images indicate bacteriochlorophyll derivative 
(Bchl-D) distribution, lower panel - red fluorescence images indicate tumor size and location. (c) Longitudinal accumulation of STL-6014, HSA-STL-
6014 and HSA-STL-7012 in large tumors. Total fluorescence intensity within the individual tumor boundaries at the indicated times, was normalized 
per unit area and expressed as photon/(sec × cm2).Goldshaid et al. Breast Cancer Research 2010, 12:R29
http://breast-cancer-research.com/content/12/3/R29
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receptors has been previously proposed to account for
the c(RGDfK)-based drug retention-enhancing effect.
MDA-MB-231 human breast cancer cells, as well as
tumor vasculature have been shown to express the αVβ3
receptor [47,48]. In a recent study [44], we clearly corre-
lated STL-6009 uptake by tumor xenografts of various
cell types, with both their vascular density and the level of
αVβ3 integrins expressed [44]. In the present study, the
free circulating c(RGDfK) competition (Figure 9) pro-
vides additional evidence with regard to the role of RGD
in active agent accumulation within tumors. However,
the observation that administration of free c(RGDfK)
molecules cannot compete with the uptake and accumu-
lation of RGD-Bchl by large necrotic tumors is not in line
with this simple explanation.
The differential response of large and small tumors to
free c(RGDfK), complements the dramatic difference in
STL-6014 accumulation patterns within the two tumor
classes. Small tumors accumulated STL-6014 over the
first four to eight hours post-drug injection, followed by
its full clearance within less than two days. In contrast,
large MDA-MB-231-RFP tumors containing necrotic
regions accumulated STL-6014 at approximately the
same rate, followed by a shift in STL-6014 localization to
the central necrosis, where it reached peak concentration
by 48 to 72 hours post-injection. This phase was followed
by slow, bi-phasic clearance (Figures 3, 4 and 6a). The
diverse clearance patterns were experimentally correlated
with the viable and necrotic domains in the tumors,
where the more rapid clearance was seen from viable
regions. This conclusion was substantiated by findings
that the fluorescence from 'large' tumors bearing small
Nv, cleared significantly faster than from tumors of simi-
lar size but with larger Nv, namely smaller viable cells
mass (Figure 4). The observation that the majority of
'small' tumors contained no or very small Nv (Figure 4)
coincided with their monoexponential and fast fluores-
c e n c e  d e c a y .  C o n v e r s e l y ,  m o r e  t h a n  9 0 %  o f  t h e  l a r g e
tumors featured large Nv, correlating with the bi-expo-
nential clearance pattern (Figures 3, 4 and 6) [see Addi-
tional file 2].
In line with these observations, we propose the pres-
ence of two distinct Bchl-D-c(RGDfK) target sites. The
first is suggested to comprise RGD-binding sites, presum-
ably integrin receptors presented on neoendothelial cells
in both small and large tumors. This site is further sug-
gested to be easily accessible to both c(RGDfK)-Bchl-D
and free c(RGDfK). The second target site correspond to
the necrotic domains, involving integrin receptors pre-
sented by the regular tumor cells, eosinophylic necrotic
tumor cells, and possibly infiltrating white blood cells.
Interaction of RGD ligands with these integrins requires
their extravasation and retention into the tumor intersti-
tium. Such extravasation can be driven in the large
necrotic tumors by the EPR effect that is relevant to the
large c(RGDfK)-Bchl-D/SA complexes but not to the
Figure 9 In Vivo inhibition of STL-6014 accumulation in small orthotopic human breast MDA-MB-231-RFP tumors by c(RGDfK). (a) CD-1 
nude, female mice bearing orthotopically grafted MDA-MB-231-RFP (n = 3) were intravenously injected with 140 nmol STL-6014. (b) CD-1 nude, fe-
male mice bearing orthotopically grafted MDA-MB-231-RFP (n = 3) were intravenously injected with 8.5 μmol c(RGDfK) and one hour later with 140 
nmol STL-6014. Fluorescent images were taken at the indicated times post-injection. Upper panel - near infrared (NIR) fluorescence images indicate 
bacteriochlorophyll derivative (Bchl-D) distribution, lower panel - red fluorescence images indicate tumor size and location. All other details are as 
described in the methods section.Goldshaid et al. Breast Cancer Research 2010, 12:R29
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small, free c(RGDfK) molecules, which rapidly clear from
the tumor [43]. Therefore, the free c(RGDfK) molecules
cannot compete with c(RGDfK)-Bchl-D binding to cellu-
lar integrins in the large tumors. The prolonged retention
of the c(RGDfK)-Bchl-D/SA within the large tumor shifts
the equilibrium of the SA-bound Bchl-D-c(RGDfK) to a
more stable, RGD-mediated interaction with the station-
ary integrin receptors through the RGD moiety. All
together, the above findings indicate that the EPR effect
may support mobilization of SA-associating therapeutic
and imaging agents into the tumor necrotic domain.
However, interactions with tumor-specific receptors are
required for the prolonged retention and accumulation of
these compounds within the tumor.
The sharp displacement of STL-6014 fluorescence from
the viable to the necrotic domain within large tumors at
increasing times after administration (Figures 4 and 5)
[see also Additional file 5] presents a feature essential to
diagnostic protocols in search of advanced tumors. This
shift is believed to be driven by the diffusion pressure cre-
ated by the imbalanced concentrations of c(RGDfK)-
Bchl-D in the viable versus necrotic tumor domains.
Neutrophils and possibly macrophages, which infiltrate
the necrotic domain (Figure 2) [1] may participate in
anchoring the migrating c(RGDfK)-Bchl-D molecules via
αVβ3 integrin receptors, expressed at high levels [49,50].
Alternatively, self-aggregation of c(RGDfK)-Bchl-D mole-
cules within the semi-aqueous necrotic domain may
occur due to their increased concentrations, shifting the
equilibrium toward further accumulation. These possibil-
ities are currently under investigation. Notably, Chen and
colleagues [26], recently showed that covalent binding of
specific cyclic RGD molecules to HSA enhances their in
vivo accumulation in tumors compared with the HSA-
free analogues. They investigators related this phenome-
non to the increased circulating t1/2 of the covalent conju-
gates (21 minutes vs. two to three minutes).
The reproducible results presented in this study have
been further supported by analysis of STL-6009 and STL-
6014 behavior in the same MDA-MB-231-RFP tumors
and in human MLS ovarian and renal cell carcinoma
tumors, respectively, at various stages of necrotic devel-
opment (data not shown).
Conclusions
Cumulatively, the presented data demonstrates selective
accumulation and prolonged retention of c(RGDfK)-
Bchl-D within the necrotic tumor domain in MDA-MB-
231-RFP bearing mice. A clear reliance on the synergistic
effect of both the RGD moiety and the agent's association
to SA was illustrated.
Although the experiments described here utilized fluo-
rescence for the selective imaging of necrotic tumors,
they are highly relevant to the clinical setting. First, the
orthotopic engraftment of human breast cancer to the
mouse mammary pad offers an environment resembling
human breast tumors. In addition, the central necrosis
described here, reflects the natural development of breast
tumors in humans. Furthermore, the RGD-mediated
accumulation characterized in the present study is of rel-
evance to human cancerous environments, where αVβ3
integrin expression is typically associated with neoves-
sels, tumor cells and macrophages abundant in the
necrotic tumor domain [47].
The described RGD/SA-mediated homing and pro-
longed retention of fluorescent Bchl-Ds in the tumor
necrotic domain may enable early detection of tumor
growth and foster prognosis and the development of
novel modes of treatment, including drug-targeted pho-
todynamic therapy. As previously reported, RGD-SA con-
trast agents [26] are likely to be immunogenic and/or
toxic in the clinical setting. The strategy suggested in the
present manuscript is not only simpler, but more versatile
and expected to present minimal toxicity. The relatively
rapid clearance of STL-6014 and other RGD-Bchl-Ds
from the liver and spleen is of utmost importance in clin-
ical application of developed drugs. Clearly, the use of
STL-6014 in the clinical setting is limited by the optical
technologies required for in-depth 3 D tumor detection.
However, optical tomography of the breast can be useful
for this purpose. Moreover, 64Cu and Mn Bchl-RGD con-
j u g a t e s  h a v e  b e e n  r e c e n t l y  p r e p a r e d  i n  o u r  l a b o r a t o r y
[37] and using inductively coupled plasma mass spectros-
copy showed to undergo similar patterns of accumulation
and retention in tumors as STL-6014. These new drugs
are expected to open the way for in vivo imaging of
deeper necrotic tumors, both in the preclinical and clini-
cal settings using PET scan and MRI spectroscopies,
respectively.
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